Endocrine Abstracts

Gender Dysphoria (GD) is defined as incongruence between gender identity and physical phenotype. This condition exists in different psychological typologies: male-to-female (MtF) and female-to-male (FtM) transsexualism. In most cases the first manifestations can occur even during childhood. The transition project is a long and difficult path that involves a multidisciplinary team including endocrinologists, psychologist and plastic surgeons. Our study aims to describe socio-de...

In MtFs therapy with oestrogens and antiandrogens, actually considered the best strategy, requires a careful baseline and follow-up hormonal evaluation. We conducted a retrospective analysis to define the most frequent hormonal treatment prescribed and the relationship between the dosage and patients’ hormonal changes. Among 85 pts referring to us between March 2003 and June 2018 with a mean age of 28.4 years we have selected 42 treated with Oestradiol Valerate (OV) and C...

In FtMs testosterone (TE) therapy is used to pursue the dual objective of suppressing female secondary sex characteristics and inducing a male phenotype to the patient. Between October 2001 and December 2018, an heterogeneous group of 32 patients (Pts) with a mean age of 27.7 years presented to our Center for FtM Gender Dysphoria. We analyzed Body Mass Index (BMI), haemochrome and hormonal (LH, FSH, Prolactin) measurements comparing baseline levels to post-therapy. A total of ...

Background: Graves’ ophthalmopathy (GO) is an autoimmune disease that affects particularly the retrobulbar soft tissues and represents the most common extrathyroidal manifestation of Graves’ disease (GD). Some studies suggest that GO in newly diagnosed patients in recent years has a trend towards a less severe clinical presentation, moreover we have no studies that focus the trend of clinical presentation of GO in the last decade on the population of our area.<p ...

Introduction: Oxidative stress (OX) plays a role in the pathogenesis of moderate to severe Graves’ ophthalmopathy (AMS-GO).Aim: We evaluated the impact of clinical conditions related to OX on the outcome of parenteral glucocorticoids (PGLUC) therapy in AMS-GO.Methods: We retrospectively evaluated patients with AMS-GO treated with PGLUC from January 2013 to May 2022. GO clinical evaluation was performed at baseline, at 6 (W6), ...

Introduction: Parenteral corticosteroids (PC) are effective for the treatment of active moderate to severe (AMS) Graves’orbitopathy(GO). A correlation of GO activity with cholesterol has been described. No evidences are available about cholesterol levels and the clinical efficacy of PC in AMS-GO.Aim: Was to detect the predictive role of cholesterol on medium term clinical outcome of PC therapy in AMS-GO.Methods: We studied 87...